Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].